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Abstract We describe the management and outcomes of
pregnancy in two women affected with Maple syrup urine
disease (MSUD). Both patients had classical disease
diagnosed in the newborn period and were managed with
low-protein diets and supplements, although compliance
was moderately poor throughout life. Both pregnancies
were complicated by poor compliance and one patient had a
metabolic decompensation, which included seizures and
profound encephalopathy, at the end of the first trimester.
Peri-partum management required a coordinated team
approach including a high-calorie and low-protein diet.
Both patients had elevated leucine levels in the post-partum
period – one due to mastitis and the other due to poor
dietary and supplement compliance combined with uterine
involution. On later review, leucine had returned to pre-
pregnancy levels. Both infants were unaffected and have
made normal developmental progress in the subsequent 1 to
2 years.
Introduction
MSUD is an autosomal recessive disorder caused by
mutations in one of three of the four genes encoding
subunits of branched-chain keto-acid dehydrogenase
(BCKAD) (Zhang et al. 1989a, b; Herring et al. 1991;
Nobukuni et al. 1991) and presents classically in the
newborn period with a maple syrup odour in cerumen and
urine, irritability and poor feeding by day 3, progressive
neurological signs, encephalopathy, coma and death if
untreated (Strauss et al. 2009). Treatment is by institution
of a very low-protein diet, branched-chain amino acid–free
supplement, and provision of calorie support at times of
decompensation. Successful treatment means that patients
are surviving into adulthood. Nevertheless, there have been
very few reports of pregnancy in MSUD.
We report the successful outcome of pregnancy in two
women affected with MSUD. A significant episode of
metabolic decompensation at the end of the first trimester
for one patient did not appear to have any effect on the
health of the infant when assessed at 4 and 20 months of
age, thus suggesting that maternal MSUD does not have a
detrimental effect on the developing fetus.
Patient 1
The patient was born following an uneventful pregnancy
and was diagnosed with classical MSUD by urine meta-
bolic screen after she presented with seizures at 10 days
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of age. She was managed with a low-protein diet and
branched-chain amino acid–free supplements (MSUD
Maxamum and MSUD Express). She had a number of
significant decompensations during the first few years of
life and was left with some neurological impairment and
very mild intellectual impairment. She adhered loosely to a
low-protein diet supplemented with MSUD Express Cool-
ers (Vitaflo Australia). Her usual intake of natural protein
was 15–35 g daily with 60 g protein from MSUD Express
Coolers . Her leucine levels were persis tent ly
500–1000 mM; unfortunately, improved compliance was
difficult to achieve. Her past medical history included panic
attacks, which were managed with fluvoxamine, and
psoriasis. Up until her pregnancy, she worked full time at
a department store.
She presented to our clinic at 10 weeks gestation. Plasma
leucine levels were elevated (708 mM) and a low-protein
diet (23 g natural protein equivalent and 60 g MSUD
Coolers) was commenced, with the intention of regular
monitoring of branched-chain amino acid levels via dried
blood spot analysis.
Our patient planned to travel overseas to visit her non-
consanguineous husband’s family. She travelled with her
dietary supplements and explicit letters of instruction for
any episodes of illness. Unfortunately, she experienced an
episode of fever and gastroenteritis after 1 week (14 weeks
gestation). She could not maintain oral intake and progres-
sively deteriorated, had a number of seizures and was said
to have been unconscious for up to 24 h. She was treated
with IV fluids and nasogastric administration of MSUD
Express Coolers at a hospital in Pakistan. She recovered
sufficiently to return to Australia, and when reviewed
shortly after her arrival she was quite well with no
neurological sequelae. Her leucine level at that time was
586 mM. There were no further episodes of decompensation
during the pregnancy.
Dietary management for the remainder of the pregnancy
included a low-protein diet with increases in allowances
over the duration of the pregnancy according to amino acid
levels (Figs. 1, 2). MSUD Express Cooler intake was
increased from 60 g to 75 g at 15 weeks gestation.
Monitoring of protein intake was by patient estimates of
intake provided by phone and email, as she lived remote
from the clinic. Pregnancy weight gain was around 15 kg
and there was not significant vomiting at any stage.
A management plan for the peri-partum period was
instituted and distributed to involved members of the
obstetric, medical, nursing and dietician staff (Table 1).
She went into spontaneous labour at 40 weeks gestation and
successfully gave birth by vaginal delivery to a baby boy
following a 7-h labour. Natural protein intake was zero on
day 1 post partum and increased by 5 g increments to her
usual pre-pregnancy intake of approximately 20 g over 1
week. The post-partum period was uneventful and she was
discharged on day 8. She subsequently presented to her
local hospital on day 12 post partum and was diagnosed
with mastitis on the basis of fever and a painful breast. Her
leucine level peaked at 549 mM. This episode was treated
with antibiotics, increased calorie intake and a reduction in
natural protein intake with a quick resolution over 3 days.
The baby’s Apgar scores were 9 and 9 at 1 and 5 min.
The birth weight was 3336 g, head circumference 34 cm
and length 51 cm. Initial testing demonstrated normal
levels of branched-chain amino acids, but elevated alloiso-
leucine that subsequently decreased (at birth ¼ 15 mM, at




























Fig. 1 Leucine levels (■ – mmol/L, left axis) and natural protein intake (x – g, right axis) plotted against gestational age. The peak at week 15
corresponds to her leucine level upon return from overseas
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not show evidence of MSUD. We interpreted the initially
elevated alloisoleucine as being maternal in origin. On
assessment at 4 months and then 20 months, he was
thriving and showed appropriate development for his age.
Patient 2
The patient initially presented at 3 days of age becoming
unwell with vomiting and increasing lethargy, progressing
to seizures and loss of consciousness at 9 days of age, and
was diagnosed with classical MSUD by urine metabolic
screen on day 15. Her childhood course of disease was
characterised by frequent recurrent metabolic decompensa-
tion, with over 70 hospitalisations by age 12 years. She had
evidence of significantly delayed development. Formally,
neuropsychological testing was consistent with moderate
intellectual disability, presumed secondary to MSUD.
She adhered to an unmeasured low-protein diet supple-
mented with MSUD Express Coolers (Vitaflo Australia)
and valine. By age 20 years, her usual intake of natural
protein was estimated to be 30–50 g daily with 20–30 g
protein from MSUD Express Coolers. Her compliance was
subopt imal and leucine levels were typical ly
700–1300 mM. Her past medical history included panic
attacks, exacerbated by poor metabolic control.
At 21 years of age, she presented to the paediatric
metabolic clinic at 27 weeks gestation, based on ultrasound
diagnosis of pregnancy 5 weeks earlier, and transferred to
adult services. One week later, she presented with an acute
febrile illness and threatened premature labour. Diagnosed
with a urinary tract infection, she was also found to be
mineral, vitamin and protein deficient. Subsequently, she
failed to attend most scheduled antenatal and metabolic




























Fig. 2 Leucine levels (■ – mmol/L, left axis) and natural protein intake (x – g, right axis) plotted against days post partum. An episode of
mastitis was diagnosed on day 12
Table 1 Management plan for the peri-partum period of patient 1
During labour and for 24 h post partum
a. EUC and blood glucose taken at every 6 h
b. Amino acids taken daily
Early labour
a. Insertion of adequate venous access by anaesthetic team
b. Food as usual
c. High-energy (no protein) supplements – Energivit 30 % aiming
for 1 L per 24 h
d. MSUD Express Cooler supplements (5  130 mL per
24 h ¼ 75 g protein)
Established labour or early labour and not tolerating oral intake
a. IV 4 % dextrose in 1/5 normal saline (+/ additional K+) at
100 mL/h
b. Intralipid 20 % (3 g/kg/day)
c. More intensive glucose + insulin therapy if required
First 24 h post partum if tolerating oral intake
a. Protein-free food (0 g natural protein)
b. High-energy (no protein) supplements – Energivit 30 % aiming
for 1 L per 24 h
c. MSUD Express Cooler supplements (5  130 mLper
24 h ¼ 75 g protein)
First 24 h post partum: if not tolerating oral intake, then TPN given
over 24 h containing
a. 1 L 10 % dextrose
b. 500 mL 20 % Intralipid
c. Standard electrolytes
d. Leucine-isoleucine-valine-free amino acids (60 g/day)
Day 2 and thereafter post partum
a. Gradual increase in dietary protein as directed by the metabolic
team/dieticians
b. High-energy (no protein) supplements – Energivit 30 % aiming
for 1 L per 24 h
c. MSUD Express Cooler supplements (4  130 mL per 24 h)
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during the second and third trimesters of pregnancy, none
was elevated with respect to leucine (Figs.3, 4). Pregnancy
weight gain was around 14 kg and there was not significant
vomiting at any stage.
She was admitted at 41 weeks gestation with suspected
rupture of membranes but had failure to progress after 12 h
which necessitated delivery by emergency lower segment
caesarean section. Natural protein intake was zero on day 1
and increased to 9 g daily over 3 days. The patient self-
discharged against medical advice on day 12 post partum
despite elevated leucine levels, although she was not
clinically encephalopathic at that time. There was consider-
able staff concern related to her social situation and
capacity to care for the child in the setting of her intellectual
disability. Implantable contraception was instituted prior to
discharge.
The baby’s Apgar scores were 9 and 9 at 1 and 5 min.
The birth weight was 3405 g, head circumference 34 cm
and length 50.5 cm. The newborn screen did not show
evidence of MSUD. Apart from obesity and reflux in the
setting of overfeeding, at 14 months of age the child has
met expected developmental milestones.
Discussion
There are three pregnancies in women with classical
MSUD documented in the literature, two of which ended
without incident (Van Calcar et al. 1992; Grunewald et al.
1998) and the third of which reported maternal death at day
51 post partum (Yoshida and Tanaka 2003), although this






































































Fig. 4 Leucine levels (■ – mmol/L, left axis) and natural protein intake (x – g, right axis) plotted against days post partum
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subsequent metabolic decompensation than a pregnancy-
related decompensation. We describe here two additional
cases demonstrating that pregnancy with a successful
outcome can be achieved. Both our patients were classified
as having “classical” MSUD, on the grounds that they
presented with symptoms in the neonatal period. However
in both, the protein tolerance before pregnancy was higher
than that of most “classical” patients and suggests a more
moderate MSUD phenotype.
We predicted two periods during which management
would need careful monitoring and adjustment. Firstly, the
increased tolerance of natural protein during the later stages
of the pregnancy was predicted as the requirements of the
fetus grow considerably during this time and maternal
physiology changes to accommodate this. Other endocrine
changes during pregnancy promote insulin resistance and
an anabolic state (Di Cianni et al. 2003), also allowing
increased protein tolerance. Careful monitoring was also
required in the post-partum period. The patient described by
Grunewald et al. had an increase in plasma leucine which
peaked at day 9 post partum (Grunewald et al. 1998). This
was thought to be as a result of a release of protein from the
involuting uterus (Lee 2006), and thus we monitored our
patients closely throughout the first 2 weeks post partum.
The episode of decompensation in patient 1 precipitated by
mastitis at day 12 post partum may have been exacerbated
by the increased protein load of the involuting uterus. The
poor metabolic control of patient 2 in the post-partum
period was thought to be due to poor dietary and
supplement compliance combined with uterine involution.
Both our patients had imperfect metabolic control
throughout their pregnancies; however, fetal outcomes were
good, despite maternal leucine levels that were grossly
elevated at times. This contrasts favourably with the
situation for maternal phenylketonuria and indicates that
leucine is not a similarly potent teratogen. The apparently
normal early development of these two children does not,
however, preclude subtle long-term effects; therefore,
children of such pregnancies should continue to be
followed long term.
Documentation of management and outcome of preg-
nancies seem important, as there are as yet few reports in
this or other inborn errors, with the exception of phenylke-
tonuria. The true risk of an adverse effect on an infant, or an
adverse post-partum event in the mother is not yet known
for MSUD, and these two further cases help to define the
situation.
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